View Older Stories View More Recent Stories

Dec 13, 2024 04:19PM Bristol-Myers Squibb (BMY) Files Mixed Shelf

Dec 11, 2024 04:18PM Bristol-Myers Squibb (BMY) Raises Quarterly Dividend 3.3% to $0.62; 4.4% Yield

Dec 11, 2024 09:44AM Truist: 'Potential Impact of Trump's Nominees on Biopharma'

Dec 3, 2024 04:57PM CFRA Downgrades BMY (BMY) to Hold Strictly on Valuation, 'we think shares are fairly valued', 'continue to see BMY as better positioned for growth'

Nov 26, 2024 01:59AM Bristol-Myers Squibb Co. (BMY) PT Raised to $62 at Bernstein SocGen Group

Nov 15, 2024 08:23AM Bristol-Myers Squibb (BMY) Receives Positive CHMP Opinion for Opdivo plus Yervoy

Nov 15, 2024 06:59AM Bristol-Myers Squibb (BMY) Receives Positive CHMP Opinion for Repotrectinib

Nov 15, 2024 02:41AM Stocks expected to have increasing option volume: AMAT ASTS BILI OKLO JD BABA WMT LOW BMY LLY AMGN GSK MRNA MRK AZN GILD NVO PCVX UNH CVX AET CI HUM WBA CELG

Nov 12, 2024 08:13AM Bristol-Myers Squibb Co. (BMY) PT Raised to $61 at BMO Capital

Nov 12, 2024 06:22AM Leerink Partners Upgrades Bristol-Myers Squibb Co. (BMY) to Outperform

Nov 11, 2024 08:40AM Bristol-Myers Squibb (BMY) Climbs 10% After AbbVie's Results for Emraclidine in Schizophrenia Did Not Meet their Primary Endpoint

Nov 4, 2024 06:20AM Bristol-Myers Squibb Co. (BMY) PT Raised to $55 at Leerink Partners

Nov 1, 2024 08:05AM Bristol-Myers Squibb Co. (BMY) PT Raised to $57 at BMO Capital

Oct 31, 2024 04:16PM Bristol-Myers Squibb (BMY) Presents New Long-term Data from the EMERGENT Program Evaluating COBENFY

Oct 31, 2024 07:01AM Bristol-Myers Squibb (BMY) Tops Q3 EPS by 30c, provides guidance

Oct 30, 2024 11:26AM Bristol-Myers Squibb (BMY) call put ratio 1.6 calls to 1 put into quarter results

Oct 7, 2024 09:29AM Bristol-Myers Squibb Co. (BMY) PT Raised to $59 at TD Cowen

Oct 4, 2024 05:59AM Bristol-Myers Squibb (BMY) Reports FDA Approval of Perioperative Treatment of Neoadjuvant Opdivo and Chemotherapy Followed by Surgery and Adjuvant Single-Agent Opdivo for Resectable NSCLC

Sep 30, 2024 07:04AM Prime Medicine (PRME) Announces Strategic Research Collaboration and License Agreement with Bristol Myers Squibb to Develop and Commercialize Multiple Prime Edited Ex Vivo T-Cell Therapies

Sep 27, 2024 11:06AM Bristol-Myers Squibb (BMY) Presents New Data from Two Trials Demonstrating Sotyktu (deucravacitinib) Efficacy in both Moderate-to-Severe Scalp Psoriasis and in a Real-World Setting

Sep 27, 2024 08:05AM Morgan Stanley on Zai Lab (ZLAB) Post BMY (BMY) Approval: 'We believe it should bode moderately positively for ZLAB shares'

Sep 27, 2024 07:44AM JPMorgan Positive on Bristol-Myers Squibb Co. (BMY): 'We Expect Strong Uptake Mid2025 and Beyond'

Sep 27, 2024 07:25AM Bristol-Myers Squibb (BMY) Climbs 5% After Schizophrenia Drug Cleared by FDA

Sep 27, 2024 07:06AM Bristol-Myers Squibb Co. (BMY) PT Raised to $53 at BMO Capital

Sep 27, 2024 06:54AM PureTech Health Plc (PRTC) -Invented KarXT Receives U.S. Food and Drug Administration Approval for the Treatment of Schizophrenia in Adults

Sep 27, 2024 06:07AM Goldman Sachs Reiterates Buy Rating on Bristol-Myers Squibb Co. (BMY)

Sep 27, 2024 06:02AM Bristol-Myers Squibb (BMY) Announces FDA Approval of COBENFY

Sep 23, 2024 07:28AM BMO Capital Reiterates Market Perform Rating on Bristol-Myers Squibb Co. (BMY)

Sep 18, 2024 06:59AM Bristol-Myers Squibb (BMY) Reports New Long-Term Zeposia Data Showing Durable Efficacy and Consistent Safety in Relapsing Forms of Multiple Sclerosis

Sep 16, 2024 05:37AM Immatics (IMTX) Presents Clinical Proof-of-Concept Data from Ongoing Phase 1 Dose Escalation Trial with TCR Bispecific Molecule

Sep 16, 2024 05:07AM Goldman Sachs Reiterates Buy Rating on Bristol-Myers Squibb Co. (BMY)

Aug 28, 2024 05:41AM Bristol-Myers Squibb Co. (BMY) PT Raised to $51 at Jefferies

Aug 21, 2024 07:00AM Bristol-Myers Squibb (BMY) Announces FDA sBLA Acceptance for First-Line Treatment of Unresectable Hepatocellular Carcinoma

Aug 19, 2024 06:59AM Bristol-Myers Squibb (BMY): EMA Validates Application for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma

Aug 12, 2024 08:13AM Bristol-Myers Squibb Co. (BMY) PT Raised to $53 at TD Cowen

Jul 29, 2024 07:18AM Bristol-Myers Squibb Co. (BMY) PT Raised to $57 at Goldman Sachs

Jul 29, 2024 06:11AM Barclays Downgrades Bristol-Myers Squibb Co. (BMY) to Underweight

Jul 26, 2024 11:27AM Midday movers: Bristol-Myers, 3M and Deckers rise; Dexcom falls

Jul 26, 2024 07:51AM Bristol-Myers Squibb (BMY) stock gains after raising full-year guidance

Jul 26, 2024 07:02AM Bristol-Myers Squibb (BMY) Tops Q2 EPS by 43c, provides guidance

Jul 25, 2024 10:47AM Bristol-Myers Squibb (BMY) call put ratio 1.6 calls to 1 put into quarter results

Jul 25, 2024 05:14AM Bristol-Myers Squibb (BMY) July 26 weekly 44.5 straddle into quarter results

Jul 25, 2024 05:08AM Bristol-Myers Squibb (BMY) July 26 weekly 44.5 straddle priced into quarter results

Jul 23, 2024 06:35AM Bristol-Myers Squibb Co. (BMY) PT Lowered to $45 at Deutsche Bank

Jul 21, 2024 06:00AM 10 policies if Trump wins and stock implications: Jefferies

Jul 19, 2024 06:59AM Bristol-Myers Squibb (BMY) Receives EMA Validation of Application for Opdivo (nivolumab) plus Yervoy (ipilimumab) for First-Line Treatment of Unresectable or Advanced Hepatocellular Carcinoma

Jul 18, 2024 09:15AM Bristol Myers Squibb Reaches Major Milestone in Environmental Sustainability

Jul 12, 2024 11:15AM Bristol-Myers Squibb Co. (BMY) PT Lowered to $43 at UBS

Jun 28, 2024 03:40PM Bristol Myers Squibb Named to Dow Jones Sustainability Index North America

Jun 24, 2024 05:45AM Bristol-Myers Squibb (BMY) Announces U.S. FDA Accelerated Approval of KRAZATI in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic

View More Recent Stories View Older Stories